Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 23.29B P/E - EPS this Y -16.80% Ern Qtrly Grth -
Income -440.24M Forward P/E -81.66 EPS next Y 57.20% 50D Avg Chg -4.00%
Sales 1.83B PEG 0.20 EPS past 5Y - 200D Avg Chg -10.00%
Dividend N/A Price/Book N/A EPS next 5Y -177.50% 52W High Chg -23.00%
Recommedations 2.10 Quick Ratio 2.86 Shares Outstanding 126.45M 52W Low Chg 4.00%
Insider Own 0.41% ROA -4.78% Shares Float 125.41M Beta 0.40
Inst Own 95.02% ROE - Shares Shorted/Prior 2.80M/3.04M Price 187.01
Gross Margin 83.02% Profit Margin -24.08% Avg. Volume 556,961 Target Price 222.68
Oper. Margin -26.47% Earnings Date May 2 Volume 618,142 Change -1.08%
About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam Pharmaceuticals, Inc. News
04/08/24 Why Alnylam Pharmaceuticals (ALNY) Stock Might be a Great Pick
04/07/24 Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension
03/29/24 Those who invested in Alnylam Pharmaceuticals (NASDAQ:ALNY) five years ago are up 63%
03/20/24 Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session
07:50 AM 30 Biggest Biotechnology Companies in the World
03/13/24 Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease
03/06/24 Alnylam (ALNY), Roche's Blood Pressure Drug Meets Study Goal
03/05/24 Roche, Alnylam say blood pressure drug succeeds in mid-stage trial
03/05/24 Alnylam, Roche blood pressure drug scores in second mid-stage trial
03/05/24 Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives
02/27/24 Alnylam to Webcast Presentations at Upcoming March Investor Conferences
08:12 AM Alnylam Pharmaceuticals Full Year 2023 Earnings: In Line With Expectations
02/16/24 Alnylam (ALNY) Q4 Loss Narrower Than Expected, Stock Dips 10%
02/16/24 Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q4 2023 Earnings Call Transcript
02/16/24 Q4 2023 Alnylam Pharmaceuticals Inc Earnings Call
02/16/24 Decoding Alnylam Pharmaceuticals Inc (ALNY): A Strategic SWOT Insight
02/15/24 Why Alnylam Pharmaceuticals Stock Is Sinking Today
02/15/24 Alnylam (ALNY) Reports Q4 Earnings: What Key Metrics Have to Say
02/15/24 Alnylam Pharmaceuticals Inc (ALNY) Reports Strong Growth in 2023, Aiming for Continued Success ...
02/15/24 Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Period Activity
ALNY Chatroom

User Image opgenopgen Posted - 1 day ago

$ALNY U.S. High Growth Tech and AI Stocks!!! https://simplywall.st/discover/investing-ideas/215171/high-growth-tech-and-ai-stocks/us?via=bullmarketstocks

User Image StockInvest_us Posted - 6 days ago

Signal alert: $ALNY - GoldenStar https://stockinvest.us/l/nBdXq8zcUm

User Image Quantumup Posted - 1 week ago

Wolfe Research $IONS Upgrading to Outperform on Catalysts (HELIOS-B & more)/Revenue Potential (SHTG & more) Sees HELIOS-B readout as risky cat, but expects favorable R/R4 $IONS movement (more so than $ALNY). Now models $2.1B peak rev for olezarsen. Pelacarsen not in model=pot upside. $vrtx

User Image tradingtwenty Posted - 1 week ago

$ALNY has trended 15 times in the past 24 hours (based on 5 minute intervals). Latest press release on Apr 07, 2024 08:00 AM: Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care... Link: https://tradingtwenty.com/news/420901/alnylam-presents-positive-results-from-the-kardia-2-phase-2-study-of-zilebesiran-added-to-standard-of-care-antihypertensives-in-patients-with-inadequately-controlled-hypertension

User Image Stock_Titan Posted - 1 week ago

$ALNY Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension https://www.stocktitan.net/news/ALNY/alnylam-presents-positive-results-from-the-kardia-2-phase-2-study-of-zkq1hsvkficn.html

User Image SorosOfPharmaeuticals Posted - 1 week ago

$ALNY With the late breaker presented on 7th April on zileberisan. Anyone want to guess impact on share price? https://investors.alnylam.com/press-release?id=28036

User Image lextrading Posted - 03/28/24

$ALNY High risk/high reward set up. High risk because it's a biotech. Next support is at $120 if the channel breaks.

User Image jaydilks Posted - 03/27/24

$VXF Best performers today. $MRVL $ALNY $RBLX

User Image pilobious Posted - 03/27/24

$ALNY chip rally finished it appears. I’m moving into biotech. ALNY and ADMA. I’m far from a biotech expert. Constructive criticism invited.

User Image Stu512 Posted - 03/26/24

$ALNY Like their call on $BLUE PT $11 ..today at $1.39 !!! Oh ya , listen to HCW

User Image Stu512 Posted - 03/26/24

$ALNY like their call on $SOL at $25, headed to $35 , today at $1.98

User Image TeresaTrades Posted - 03/22/24

Heavy options volume $MJ $LULU $ALNY $PZZA $CRON

User Image pilobious Posted - 03/21/24

$ALNY this sells off every day. $150 this morning got whacked. I’m down big and holding.

User Image Quantumup Posted - 03/21/24

Raymond James resumed $BBIO Outperform/$45: Believes oral TTR-stabilizers will remain the gold-standard 1st-line Tx for pts w/ ATTR-CM. Re: IP overhang: there are +VE signs $PFE will be successful; If patent holds, ests $BBIO = $3B peak/20% of est'd $15B TAM, w/ uncertainty $1.6B. $alny

User Image Stock_Titan Posted - 03/20/24

$ALNY Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session https://www.stocktitan.net/news/ALNY/alnylam-to-webcast-investor-event-to-discuss-results-from-kardia-2-em6s08uotu95.html

User Image G101SPM Posted - 1 month ago

@S_Franconi per request: $ALNY carries SPM 83.25 tag.

User Image S_Franconi Posted - 1 month ago

@G101SPM Can you run $ALNY?

User Image Quantumup Posted - 1 month ago

BMO Capital $SLN "Weakness a Unique Opportunity to buy the dip;" Reiterated as Top Pick~$67/OP Despite the fact Zirlesiran data "met/beat" inv expys, SLN is down. BMO reits high conviction on 2 de-risked/differentiated programs=multi-billion$ comm opps; low valuation vs peers; '24 catalyst. $alny $ions $arwr

User Image ksoption Posted - 1 month ago

$ALNY

User Image Stock_Titan Posted - 1 month ago

$ALNY Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease https://www.stocktitan.net/news/ALNY/alnylam-launches-hereditary-attr-h-attr-amyloidosis-campaign-to-help-931mt392pyga.html

User Image addtocart Posted - 1 month ago

$ALNY yeah this looks good here

User Image swingingtech Posted - 1 month ago

$ALNY $RHHBY https://wallstreetwaves.com/roche-alnylam-blood-pressure-drug-aces-in-mid-stage-trial-analyst-says-zilebesiran-as-promising-op

User Image Thestocktraderhubzee Posted - 1 month ago

$ALNY HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $395 Price Target

User Image piano91 Posted - 1 month ago

$ALNY 1.2 billion people effected here and zilebesiran will be standard of care. Roche marketing worldwide and Alnylam in US. Should bring over 3-4B in rev

User Image DonCorleone77 Posted - 1 month ago

$ALNY Alnylam reports KARDIA-2 zilebesiran study met primary endpoint of lower SBP Alnylam Pharmaceuticals announced that the KARDIA-2 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen AGT in development for the treatment of hypertension, met the primary endpoint showing that zilebesiran resulted in clinically and statistically significant additive, placebo-adjusted reductions in 24-hour mean systolic blood pressure SBP at Month 3 as measured by ambulatory blood pressure monitoring ABPM in each of three independent patient cohorts receiving the standardized background therapies of either a thiazide-like diuretic or indapamide, calcium channel blocker, amlodipine, or angiotensin receptor blocker ot olmesartan. Zilebesiran demonstrated an encouraging safety and tolerability profile when added to these standard of care antihypertensives. The Company believes these findings support further development....

User Image Stock_Titan Posted - 1 month ago

$ALNY Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives https://www.stocktitan.net/news/ALNY/alnylam-reports-positive-kardia-2-topline-study-results-tt3pgu60yh9q.html

User Image valueforme Posted - 1 month ago

$OMGA Ha! The CEO has mentioned during this podcast that the obesity program that they are going to work on with Novo Nordisk will target adipose tissue. Hmm, where I've heard this before.. Let me think. Ah, yes, INHBE programs that $WVE , $ARWR and $ALNY are going to file IND for over next 12 months. So this is getting even more interesting. Not just s battle of siRNA chemistry approaches, but also epigenetics down regulation from OMGA as an alternative. O boy, o boy, o boy, this is going to be a fun decade https://thebioreport.podbean.com/e/correcting-gene-dysregulation-to-treat-diseases/

User Image Biotech_Beast Posted - 02/28/24

$VIR has something promising in Hepatitis Delta and more data are on tap in Q2'24. Additional Hepatitis B data in Q4'24. $ALNY $GSK https://seekingalpha.com/article/4674087-vir-biotechnology-stock-making-progress-in-hepatitis-b-hepatitis-delta

User Image JGNYC Posted - 02/27/24

$ALNY waiting for entry

User Image Stock_Titan Posted - 02/27/24

$ALNY Alnylam to Webcast Presentations at Upcoming March Investor Conferences https://www.stocktitan.net/news/ALNY/alnylam-to-webcast-presentations-at-upcoming-march-investor-4ykitc2l9npl.html

Analyst Ratings
BMO Capital Outperform Mar 27, 24
HC Wainwright & Co. Buy Mar 5, 24
Cantor Fitzgerald Neutral Feb 23, 24
RBC Capital Outperform Feb 21, 24
Cantor Fitzgerald Neutral Feb 20, 24
RBC Capital Outperform Feb 20, 24
Wells Fargo Equal-Weight Feb 16, 24
Citigroup Buy Feb 16, 24
RBC Capital Outperform Feb 16, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Garg Pushkal CMO & EVP Dev & Med.. CMO & EVP Dev & Med Affairs Aug 03 Sell 186.14 7,627 1,419,690 4,345 08/07/23
Poulton Jeffrey V. EVP, Chief Financial.. EVP, Chief Financial Officer Aug 03 Sell 186.95 3,460 646,847 15,873 08/07/23
Greenstreet Yvonne Chief Executive Offi.. Chief Executive Officer Aug 03 Sell 186.95 4,057 758,456 35,216 08/07/23
Vaishnaw Akshay President President Aug 03 Sell 186.95 4,057 758,456 22,774 08/07/23
Greenstreet Yvonne Chief Executive Offi.. Chief Executive Officer Apr 26 Sell 194.96 7,615 1,484,620 30,332 04/28/23
Poulton Jeffrey V. EVP, Chief Financial.. EVP, Chief Financial Officer Apr 26 Sell 194.96 977 190,476 11,706 04/28/23
Tanguler Tolga EVP, Chief Commercia.. EVP, Chief Commercial Officer Apr 26 Sell 194.96 1,476 287,761 1,801 04/28/23
Vaishnaw Akshay President President Apr 26 Sell 194.96 2,392 466,344 17,890 04/28/23
Garg Pushkal CMO & EVP Dev & Med.. CMO & EVP Dev & Med Affairs Apr 26 Sell 196.92 4,294 845,574 4,345 04/28/23
Franchini Indrani Lall EVP, CLO & Secretary EVP, CLO & Secretary Feb 01 Sell 225.94 1,675 378,450 3,500 02/03/23
Franchini Indrani Lall EVP, CLO & Secretary EVP, CLO & Secretary Feb 01 Option 0 5,175 5,175 02/03/23
Tanguler Tolga EVP, Chief Commercia.. EVP, Chief Commercial Officer Feb 01 Sell 228.76 5,025 1,149,519 02/03/23
Tanguler Tolga EVP, Chief Commercia.. EVP, Chief Commercial Officer Feb 01 Option 0 5,025 5,025 02/03/23
Tanguler Tolga EVP, Chief Commercia.. EVP, Chief Commercial Officer Jul 05 Sell 150.0 1,754 263,100 1,754 07/07/22
Vaishnaw Akshay President, R&D President, R&D Dec 21 Sell 190.24 2,879 547,701 11,215 12/23/21
MARAGANORE JOHN Chief Executive Offi.. Chief Executive Officer Nov 12 Sell 172.3 33,978 5,854,409 214,765 11/12/21
MARAGANORE JOHN Chief Executive Offi.. Chief Executive Officer Nov 12 Option 7.1 33,978 241,244 248,743 11/12/21
MARAGANORE JOHN Chief Executive Offi.. Chief Executive Officer May 17 Option 7.1 33,979 241,251 248,744 05/17/21
MARAGANORE JOHN Chief Executive Offi.. Chief Executive Officer May 17 Sell 131.34 33,979 4,462,802 214,765 05/17/21
Vaishnaw Akshay President, R&D President, R&D Apr 21 Sell 137.67 6,438 886,319 14,119 04/21/21
MARAGANORE JOHN Chief Executive Offi.. Chief Executive Officer Feb 26 Option 7.1 33,979 241,251 240,015 02/26/21
MARAGANORE JOHN Chief Executive Offi.. Chief Executive Officer Feb 26 Sell 149.18 33,979 5,068,987 206,036 02/26/21
KEATING LAURIE EVP, Chief Legal Off.. EVP, Chief Legal Officer Jan 15 Option 81.2 9,027 732,992 11,261 01/15/21
KEATING LAURIE EVP, Chief Legal Off.. EVP, Chief Legal Officer Jan 15 Sell 171 9,027 1,543,617 2,234 01/15/21
PAUL STEVEN M Director Director Dec 22 Option 9.3 15,000 139,500 16,000 12/22/20
PAUL STEVEN M Director Director Dec 22 Sell 140 15,000 2,100,000 1,000 12/22/20
SHARP PHILLIP A Director Director Nov 30 Option 9.3 30,000 279,000 265,633 11/30/20
SHARP PHILLIP A Director Director Nov 30 Sell 125.74 30,000 3,772,200 235,633 11/30/20
MARAGANORE JOHN Chief Executive Offi.. Chief Executive Officer Nov 20 Option 9.14 34,765 317,752 232,354 11/20/20
MARAGANORE JOHN Chief Executive Offi.. Chief Executive Officer Nov 20 Sell 125 34,765 4,345,625 197,589 11/20/20
Vaishnaw Akshay President, R&D President, R&D Oct 01 Option 42.22 971 40,996 15,090 10/01/20
Vaishnaw Akshay President, R&D President, R&D Oct 01 Sell 140 971 135,940 14,119 10/01/20